What Are Nanobodies? A Deep Dive into Single-Domain and Camelid Antibodies

Introduction to Nanobodies and sdAbs

What Is a Nanobody?

Nanobodies—also known as single-domain antibodies (sdAbs) or VHHs—are the antigen-binding fragments derived from the heavy-chain-only antibodies naturally produced by camelids. Unlike conventional IgG, which consists of two heavy and two light chains, camelid heavy-chain antibodies lack light chains entirely; their variable domain (VHH) alone is sufficient to recognize antigen with high affinity.

Terminology

• "Nanobody" is a common trade name for camelid VHH domains, reflecting their nanoscale molecular weight (~12–15 kDa).
• VHH (Variable Heavy-chain domain of Heavy-chain antibody)
• The single immunoglobulin domain that mediates antigen binding.
• sdAb (Single-Domain Antibody)

VHH Structure and Distinguishing Features

Nanobody (VHH) domains adopt the prototypical immunoglobulin β-sandwich fold—two antiparallel β-sheets bridged by a conserved disulfide bond—yet at just 12–15 kDa they are roughly one-tenth the size of a full IgG. A hallmark is their extended CDR3 loop, which often protrudes 5–10 amino acids further than conventional VH CDR3s. This architectural feature creates a convex paratope capable of engaging recessed or enzyme-active sites that are inaccessible to larger antibodies.

Their single-domain format confers several functional advantages in vitro and in vivo:

• Compactness & Solubility: VHH frameworks have evolved hydrophilic surface residues in place of the typical VL-VH interface, greatly reducing aggregation and enabling high-concentration formulations.
• Thermal & pH Stability: Many VHHs retain binding activity after exposure to 60–80 °C or to extremes of pH, making them robust reagents for harsh assay conditions.
• Rapid Tissue Penetration: At one-tenth the hydrodynamic radius of IgG, nanobodies diffuse more readily into dense tissues and solid tumors—ideal for imaging and in situ diagnostics.

Camelid Antibodies vs. Conventional IgG

Heavy-chain–only antibodies first appeared in camelids via a natural gene-deletion event that eliminated the CH1 domain and light-chain locus. Their VHH domains are structurally distinct from human VH domains:

• Framework Substitutions: Key framework residues (e.g., FR2 “hallmarks” at positions 37, 44, 45, 47) increase solubility by replacing buried hydrophobic patches.
• Single-Chain Autonomy: Absence of VL simplifies engineering, expression in microbial hosts (E. coli, yeast), and multimerization strategies without requiring a light-chain partner.
• Evolutionary Adaptation: Camelids evolved these antibodies to mount effective immune responses in extreme environments (deserts, high altitudes), selecting for small, stable, and versatile binding domains.

Together, these structural and evolutionary innovations make VHH domains uniquely suited for applications spanning high-resolution structural biology, point-of-care diagnostics, and next-generation therapeutic formats—from bispecific constructs to intracellular intrabodies.

At the heart of our Nanobody Discovery Service lies a streamlined three-phase workflow:

1. Llama Immunization & Bleed
   We immunize llamas at our Wuhan farm with your purified antigen, then collect blood once VHH titers peak.
2. Library Construction
   VHH-encoding transcripts are amplified, cloned into a high-diversity phage-display library (>10⁹ unique variants), and displayed on filamentous phage.
3. High-Throughput Screening
   Iterative rounds of panning enrich target-specific binders. Next-generation sequencing monitors clone frequencies, and biolayer interferometry (BLI) quantifies binding kinetics to select top candidates.

Discovery Pipeline Overview

From antigen design to validated VHHs, our fully integrated platform covers:

• Antigen formulation & llama immunization
• VHH gene amplification & library creation
• Phage-display panning & enrichment
• Kinetic profiling (NGS, BLI)
• Recombinant expression and candidate qualification

Each step is optimized for maximal diversity, rapid binder identification, and seamless hand-off to downstream engineering.

To help you determine whether a nanobody is the optimal format for your project, we’ve included a dedicated Decision Guide: Is a Nanobody Right for You? section on our main offer page.